BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition

Although targeting oncogenic mutations in the BRAF serine/threonine kinase with small molecule inhibitors can lead to significant clinical responses in melanoma, it fails to eradicate tumors in nearly all patients. Successful therapy will be aided by identification of intrinsic mechanisms that prote...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Haq, Rizwan, Yokoyama, Satoru, Hawryluk, Elena B., Jönsson, Göran B., Frederick, Dennie Tompers, McHenry, Kevin, Porter, Dale, Tran, Thanh-Nga, Love, Kevin T., Langer, Robert, Anderson, Daniel G., Garraway, Levi A., Duncan, Lyn McDivitt, Morton, Donald L., Hoon, Dave S. B., Wargo, Jennifer A., Song, Jun S., Fisher, David E.
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2013
Assuntos:
Biological Sciences
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3600451/
https://ncbi.nlm.nih.gov/pubmed/23447565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1205575110
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados